MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Tekla Life Sciences Investors

Financial Services US HQL

14.85USD
0.30(2.06%)

Last update at 2024-07-11T14:49:00Z

Day Range

14.5814.88
LowHigh

52 Week Range

11.0613.62
LowHigh

Fundamentals

  • Previous Close 14.55
  • Market Cap354.98M
  • Volume53040
  • P/E Ratio16.77
  • Dividend Yield9.66%
  • Revenue TTM3.51M
  • Revenue Per Share TTM0.13
  • Gross Profit TTM 3.02M
  • Diluted EPS TTM0.79

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax 22.35M -104.60310M 64.53M 123.05M -70.47862M
Minority interest - - - - -
Net income 22.35M -104.60310M 64.53M 123.05M -70.47862M
Selling general administrative 0.90M 1.08M 0.84M 0.75M 0.88M
Selling and marketing expenses - - - - -
Gross profit 23.52M -103.25043M 65.69M 124.08M -69.34210M
Reconciled depreciation - - - - -
Ebit - -2.99013M -4.13902M -2.11469M -70.47862M
Ebitda 22.35M -104.60310M 64.53M 123.05M -70.47862M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 22.35M -104.60310M 64.53M 123.05M -70.47862M
Other operating expenses 1.17M 1.35M 1.16M 1.03M 1.14M
Interest expense - - 0.00000M 0.00000M 67.60M
Tax provision - - - - -
Interest income 0.20M 0.05M 68.67M 0.16M 67.60M
Net interest income 0.20M 0.05M - 0.16M 0.22M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 23.52M -103.25043M 65.69M 124.08M -69.34210M
Total operating expenses 1.17M 1.35M 1.16M 1.03M 1.14M
Cost of revenue - - 5.60M 4.78M 4.48M
Total other income expense net - - - - -67.59959M
Discontinued operations - - - - -
Net income from continuing ops 22.35M -104.60310M 64.53M 123.05M -70.47862M
Net income applicable to common shares - -104.60310M 64.53M 123.05M -70.47862M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 402.60M 414.73M 534.19M 484.17M 386.98M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 11.09M 8.46M 4.97M 12.03M
Total liab 0.67M 16.82M 10.75M 0.60M 2.82M
Total stockholder equity 401.93M 397.90M 523.44M 483.57M 383.65M
Deferred long term liab - - - - -
Other current liab - -5.09971M - - -2.82473M
Common stock 0.27M 0.26M 0.25M 0.24M 345.29M
Capital stock 0.27M 0.26M 0.25M 0.24M 345.29M
Retained earnings -1.48123M 9.55M 150.70M 127.03M 38.36M
Other liab - - - 0.01M -
Good will - - - - -
Other assets 0.03M 0.03M 0.03M 0.12M 0.42M
Cash 0.00048M 0.00044M 0.00099M - 1.12M
Cash and equivalents - - - - -
Total current liabilities - 5.10M 10.75M 0.58M 2.82M
Current deferred revenue - - - - -
Net debt -0.00048M -0.00044M -0.00099M - -1.12314M
Short term debt - - 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 403.15M 388.10M 372.49M 356.30M -0.00000M
Property plant equipment - - - - -
Total current assets 5.05M 0.62M 0.14M 0.07M 5.09M
Long term investments 397.53M 414.08M 534.01M 483.97M 381.47M
Net tangible assets - 397.90M 523.44M 483.57M 383.65M
Short term investments - - - - -
Net receivables 5.04M 0.62M 0.14M 0.07M 3.97M
Long term debt - - - - -
Inventory - - - - -
Accounts payable - 5.10M - - 2.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.24M 345.29M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -397.52908M -414.07608M -534.00769M -483.97305M -381.47106M
Deferred long term asset charges - - - - -
Non current assets total 397.53M 414.08M 534.01M 483.97M 381.47M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments - - - - -
Change to liabilities - 0.00000M 0.00000M 0.00000M 0.00000M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities - - - - -
Change to operating activities - - - - -
Net income 22.35M -104.60310M 64.53M 123.05M -70.47862M
Change in cash - - - - -
Begin period cash flow - - - - -
End period cash flow - - - - -
Total cash from operating activities - - - - -
Issuance of capital stock - - - - -
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - -
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Financial Services Industry: Asset Management

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
HQL
Tekla Life Sciences Investors
0.30 2.06% 14.85 16.77 - 101.05 0.88
BX
Blackstone Group Inc
2.90 2.34% 127.17 54.68 21.93 18.77 13.26 8.40
BLK
BlackRock Inc
11.46 1.41% 823.47 34.48 22.47 6.68 3.04 6.82 15.82
KKR
KKR & Co LP
0.38 0.35% 109.83 29.90 16.84 4.76 3.56 2.50 4.66
IVSBF
Investor AB ser. B
0.20 0.76% 26.60 6.10 - 0.41 1.04 0.24 1.68

Reports Covered

Stock Research & News

Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Tekla Life Sciences Investors

100 Federal Street, Boston, MA, United States, 02110

Key Executives

Name Title Year Born
Dr. Daniel R. Omstead M.S, Ph.D. Principal Exec. Officer, Pres and Trustee 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.